A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease

Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160 · see citing works

Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C. A., Hardy, J., Duff, K., Jantzen, P. T., DiCarlo, G., Wilcock, D. M., et al. (2000) · Nature · doi:10.1038/35050116 · Cited by 1,488 · see citing works

Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431 · see citing works

Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report

Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · see citing works

Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization

Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356 · see citing works

Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo

Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599 · see citing works

Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer's Disease

Ferrer, I., Boada, M., Guerra, M. L. S., Rey, M. J., & Costa‐Jussà, F. R. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00493.x · Cited by 567 · see citing works

Cerebral Hemorrhage After Passive Anti-Aβ Immunotherapy

Pfeifer, M., Boncristiano, S., Bondolfi, L., Stalder, A., Deller, T., Staufenbiel, M., Mathews, P. M., & Jucker, M. (2002) · Science · doi:10.1126/science.1078259 · Cited by 511 · see citing works

Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4–10 and inhibit cytotoxicity and fibrillogenesis

McLaurin, J., Cecal, R., Kierstead, M. E., Tian, X., Phinney, A. L., Manea, M., French, J. E., Lambermon, M. H. L., Darabie, A. A., Brown, M. E., et al. (2002) · Nature Medicine · doi:10.1038/nm790 · Cited by 412 · see citing works

Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease

Masliah, E., Hansen, L., Adame, A., Crews, L. A., Bard, F., Lee, C., Seubert, P. A., Games, D., Kirby, L., & Schenk, D. (2005) · Neurology · doi:10.1212/01.wnl.0000148590.39911.df · Cited by 355 · see citing works

Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of Amyloid β

Racke, M. M., Boone, L. I., Hepburn, D. L., Parsadainian, M., Bryan, M. T., Ness, D. K., Piroozi, K. S., Jordan, W. H., Brown, D. D., Hoffman, W. P., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4337-04.2005 · Cited by 320 · see citing works

Prevalence and severity of microbleeds in a memory clinic setting

Cordonnier, C., van der Flier, W. M., Sluimer, J. D., Leys, D., Barkhof, F., & Scheltens, P. (2006) · Neurology · doi:10.1212/01.wnl.0000210535.20297.ae · Cited by 305 · see citing works

Aβ42 immunization in Alzheimer's disease generates Aβ N-terminal antibodies

Lee, M., Bard, F., Johnson‐Wood, K., Lee, C., Hu, K., Griffith, S. G., Black, R. S., Schenk, D., & Seubert, P. A. (2005) · Annals of Neurology · doi:10.1002/ana.20592 · Cited by 129 · see citing works

Progress in the Active Immunotherapeutic Approach to Alzheimer’s Disease: Clinical Investigations into AN1792-Associated Meningoencephalitis

Pride, M. W., Seubert, P. A., Grundman, M., Hagen, M., Eldridge, J. H., & Black, R. S. (2008) · Neurodegenerative Diseases · doi:10.1159/000113700 · Cited by 118 · see citing works

Cerebral amyloid angiopathy: Both viper and maggot in the brain

Weller, R. O., & Nicoll, J. A. R. (2005) · Annals of Neurology · doi:10.1002/ana.20622 · Cited by 25 · see citing works

New directions towards safer and effective vaccines for Alzheimer's disease.

Goñi, F., & Sigurdsson, E. M. (2005) · PubMed · Cited by 25 · see citing works

Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature

Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · see citing works

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup

Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857 · see citing works

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients with Early Alzheimer Disease

Salloway, S., Chalkias, S., Barkhof, F., Burkett, P., Barakos, J., Purcell, D., Suhy, J., Forrestal, F., Tian, Y., Umans, K., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.4161 · Cited by 619 · see citing works

Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise

van Dyck, C. H. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.010 · Cited by 568 · see citing works

Functional Alterations in Memory Networks in Early Alzheimer’s Disease

Sperling, R. A., Dickerson, B. C., Pihlajamaki, M. M., Vannini, P., LaViolette, P. S., Vitolo, O. V., Hedden, T., Becker, J. A., Rentz, D. M., Selkoe, D. J., et al. (2010) · NeuroMolecular Medicine · doi:10.1007/s12017-009-8109-7 · Cited by 587 · see citing works

Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease

Barage, S. H., & Sonawane, K. D. (2015) · Neuropeptides · doi:10.1016/j.npep.2015.06.008 · Cited by 579 · see citing works

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis

Sperling, R., Salloway, S., Brooks, D. J., Tampieri, D., Barakos, J., Fox, N. C., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70015-7 · Cited by 512 · see citing works

A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice

DeMattos, R. B., Lu, J., Tang, Y., Racke, M. M., DeLong, C. A., Tzaferis, J. A., Hole, J. T., Forster, B. M., McDonnell, P. C., Liu, F., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.10.029 · Cited by 442 · see citing works

Alzheimer’s disease is not “brain aging”: neuropathological, genetic, and epidemiological human studies

Nelson, P. T., Head, E., Schmitt, F. A., Davis, P. R., Neltner, J. H., Jicha, G. A., Abner, E. L., Smith, C. D., Van Eldik, L. J., Kryscio, R. J., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0826-y · Cited by 365 · see citing works

Validation of Clinicoradiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy–Related Inflammation

Auriel, E., Charidimou, A., Gurol, M. E., Ni, J., van Etten, E. S., Martínez‐Ramírez, S., Boulouis, G., Piazza, F., DiFrancesco, J. C., Frosch, M. P., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.4078 · Cited by 360 · see citing works

The Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer's Disease

Brothers, H. M., Gosztyla, M. L., & Robinson, S. R. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00118 · Cited by 314 · see citing works

Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer’s disease: a systematic review

Jeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306 · see citing works

A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease

Karran, E. H., & Hardy, J. (2014) · Annals of Neurology · doi:10.1002/ana.24188 · Cited by 275 · see citing works

Current and Emerging Drug Treatment Options for Alzheimerʼs Disease

Herrmann, N., Chau, S. A., Kircanski, I., & Lanctôt, K. L. (2011) · Drugs · doi:10.2165/11595870-000000000-00000 · Cited by 238 · see citing works

Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors

Tayeb, H. O., Yang, H. D., Price, B. H., & Tarazi, F. I. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.12.002 · Cited by 231 · see citing works

Cerebral Microbleeds: A Review of Clinical, Genetic, and Neuroimaging Associations

Yates, P. A., Villemagne, V. L., Ellis, K. A., Desmond, P. M., Masters, C. L., & Rowe, C. C. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2013.00205 · Cited by 231 · see citing works

Immunotherapy for Alzheimer’s disease: Key Symposium: Immunotherapy for Alzheimer’s disease

Morgan, D. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02315.x · Cited by 225 · see citing works

A review on advances of treatment modalities for Alzheimer's disease

Thoe, E. S., Fauzi, A., Tang, Y.-Q., Chamyuang, S., & Chia, A. Y. Y. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119129 · Cited by 224 · see citing works

Chronic Rapamycin Restores Brain Vascular Integrity and Function Through NO Synthase Activation and Improves Memory in Symptomatic Mice Modeling Alzheimer’s Disease

Lin, A., Zheng, W., Halloran, J. J., Burbank, R. R., Hussong, S. A., Hart, M. J., Javors, M. A., Shih, Y. I., Muir, E. R., Fonseca, R. S., et al. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.82 · Cited by 208 · see citing works

Predicting MCI outcome with clinically available MRI and CSF biomarkers

Heister, D. S., Brewer, J. B., Magda, S., Blennow, K., McEvoy, L. K., & Initiative, A. D. N. (2011) · Neurology · doi:10.1212/wnl.0b013e3182343314 · Cited by 201 · see citing works

Reengineering Biopharmaceuticals for Targeted Delivery Across the Blood–Brain Barrier

Pardridge, W. M., & Boado, R. J. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-396962-0.00011-2 · Cited by 199 · see citing works

First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease

Ferrero, J., Williams, L., Stella, H., Leitermann, K., Mikulskis, A., O'Gorman, J., & Sevigny, J. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.06.002 · Cited by 189 · see citing works

Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy

Barakos, J. A., Purcell, D. D., Suhy, J., Chalkias, S., Burkett, P., Grassi, C. M., Castrillo‐Viguera, C., Rubino, I., & Vijverberg, E. G. B. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.21 · Cited by 170 · see citing works

Second-generation anti-amyloid monoclonal antibodies for Alzheimer’s disease: current landscape and future perspectives

Kim, B., Kim, S., Nam, Y., Park, Y., Shin, S. M., & Moon, M. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00465-w · Cited by 159 · see citing works

Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection and Reporting Recommendations for Clinical Practice

Cogswell, P. M., Barakos, J. A., Barkhof, F., Benzinger, T. L. S., Jack, C. R., Poussaint, T. Y., Raji, C. A., Ramanan, V. K., & Whitlow, C. T. (2022) · American Journal of Neuroradiology · doi:10.3174/ajnr.a7586 · Cited by 146 · see citing works

Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer’s disease from a ferroptosis perspective

Derry, P. J., Hegde, M. L., Jackson, G. R., Kayed, R., Tour, J. M., Tsai, A.-L., & Kent, T. A. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101716 · Cited by 142 · see citing works

Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study

Vandenberghe, R. R., Riviere, M., Caputo, A., Sóvágó, J., Maguire, R. P., Farlow, M. R., Marotta, G., Sánchez‐Valle, R., Scheltens, P., Ryan, J. M., et al. (2016) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.12.003 · Cited by 146 · see citing works

Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody

Pardridge, W. M. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.952627 · Cited by 152 · see citing works

Immunotherapy for Alzheimer‘s Disease: From Anti-β-Amyloid to Tau-Based Immunization Strategies

Panza, F., Frisardi, V., Solfrizzi, V., Imbimbo, B. P., Logroscino, G., Santamato, A., Greco, A., Seripa, D., & Pilotto, A. (2012) · Immunotherapy · doi:10.2217/imt.11.170 · Cited by 125 · see citing works

Bapineuzumab and solanezumab for Alzheimer's disease: is the ‘amyloid cascade hypothesis’ still alive?

Tayeb, H. O., Murray, E. D., Price, B. H., & Tarazi, F. I. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.789856 · Cited by 119 · see citing works

MR Imaging Features of Amyloid-Related Imaging Abnormalities

Barakos, J. A., Sperling, R. A., Salloway, S., Jack, C. R., Gass, A., Fiebach, J. B., Tampieri, D. I., Melançon, D., Miaux, Y., Rippon, G. A., et al. (2013) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3500 · Cited by 120 · see citing works

ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease

Honig, L. S., Barakos, J. A., Dhadda, S., Kanekiyo, M., Reyderman, L., Irizarry, M. C., Kramer, L. D., Swanson, C. J., & Sabbagh, M. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12377 · Cited by 110 · see citing works

ADDLs and the signaling web that leads to Alzheimer’s disease

Krafft, G. A., & Klein, W. L. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.07.012 · Cited by 111 · see citing works

Gantenerumab: An anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

Bateman, R. J., Cummings, J., Schobel, S., Salloway, S., Vellas, B., Boada, M., Black, S. E., Blennow, K., Fontoura, P., Klein, G., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01110-8 · Cited by 109 · see citing works

Clinical Trials in Alzheimer’s Disease: A Hurdle in the Path of Remedy

Oxford, A. E., Stewart, E. S., & Rohn, T. T. (2020) · International Journal of Alzheimer s Disease · doi:10.1155/2020/5380346 · Cited by 109 · see citing works

Mild Cognitive Impairment: Baseline and Longitudinal Structural MR Imaging Measures Improve Predictive Prognosis

McEvoy, L. K., Holland, D., Hagler, D. J., Fennema‐Notestine, C., Brewer, J. B., & Dale, A. M. (2011) · Radiology · doi:10.1148/radiol.11101975 · Cited by 107 · see citing works

Two Phase 2 Multiple Ascending–Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer’s Disease

Pasquier, F., Sadowsky, C., Holstein, A. R., Prince, G. L., Peng, Y., Jackson, N. M., Fox, N. C., Ketter, N., Liu, E., Ryan, J. M., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150376 · Cited by 105 · see citing works

Safety and Efficacy of Monoclonal Antibodies for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials

Lacorte, E., Ancidoni, A., Zaccaria, V., Remoli, G., Tariciotti, L., Bellomo, G., Sciancalepore, F., Corbo, M., Lombardo, F. L., Bacigalupo, I., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220046 · Cited by 100 · see citing works

Amyloid-Related Imaging Abnormalities: An Update

Roytman, M., Mashriqi, F., Al-Tawil, K., Schulz, P. E., Zaharchuk, G., Benzinger, T. L. S., & Franceschi, A. M. (2023) · American Journal of Roentgenology · doi:10.2214/ajr.22.28461 · Cited by 99 · see citing works

Amyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta pores.

Arbor, S., LaFontaine, M., & Cumbay, M. G. (2016) · Europe PMC (PubMed Central) · Cited by 92 · see citing works

Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease

Imbimbo, B. P., Ottonello, S., Frisardi, V., Solfrizzi, V., Greco, A., Seripa, D., Pilotto, A., & Panza, F. (2012) · Expert Review of Clinical Immunology · doi:10.1586/eci.11.93 · Cited by 90 · see citing works

Amyloid-related Imaging Abnormalities in Alzheimer Disease Treated with Anti–Amyloid-β Therapy

Agarwal, A., Gupta, V., Brahmbhatt, P., Desai, A., Vibhute, P., Joseph-Mathurin, N., & Bathla, G. (2023) · RadioGraphics · doi:10.1148/rg.230009 · Cited by 90 · see citing works

Quantitative structural MRI for early detection of Alzheimer's disease

McEvoy, L. K., & Brewer, J. B. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.162 · Cited by 90 · see citing works

Targeting Beta Amyloid: A Clinical Review of Immunotherapeutic Approaches in Alzheimer's Disease

Lobello, K., Ryan, J. M., Liu, E., Rippon, G. A., & Black, R. S. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/628070 · Cited by 86 · see citing works

Near-Infrared Fluorescent Probes as Imaging and Theranostic Modalities for Amyloid-Beta and Tau Aggregates in Alzheimer’s Disease

Rai, H., Gupta, S., Kumar, S., Yang, J., Singh, S. K., Ran, C., & Modi, G. P. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01619 · Cited by 86 · see citing works

Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials

Abushouk, A. I., Elmaraezy, A., Aglan, A. D., Salama, R., Fouda, S., Fouda, R., & AlSafadi, A. M. (2017) · BMC Neurology · doi:10.1186/s12883-017-0850-1 · Cited by 86 · see citing works

Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer’s Disease Patients

Ketter, N., Brashear, H. R., Bogert, J., Di, J., Miaux, Y., Gass, A., Purcell, D. D., Barkhof, F., & Arrighi, H. M. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160216 · Cited by 80 · see citing works

Biomarkers in Amyloid-β Immunotherapy Trials in Alzheimer’s Disease

Blennow, K., Hampel, H. J., & Zetterberg, H. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.154 · Cited by 79 · see citing works

Current pharmacotherapy and putative disease-modifying therapy for Alzheimer’s disease

Kulshreshtha, A., & Piplani, P. (2016) · Neurological Sciences · doi:10.1007/s10072-016-2625-7 · Cited by 75 · see citing works

Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations

Webster, L., Groskreutz, D., Grinbergs‐Saull, A., Howard, R. J., O'Brien, J. T., Mountain, G. A., Banerjee, S., Woods, B. T., Perneczky, R., Lafortune, L., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21260 · Cited by 73 · see citing works

Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy

Vasilevko, V., Passos, G. F., Quiring, D., Head, E., Kim, R. C., Fisher, M., & Cribbs, D. H. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05786.x · Cited by 72 · see citing works

The amyloid-β degradation pattern in plasma—A possible tool for clinical trials in Alzheimer's disease

Pannee, J., Törnqvist, U., Westerlund, A., Ingelsson, M., Lannfelt, L., Brinkmalm, G., Persson, R., Gobom, J., Svensson, J., Johansson, P., et al. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.04.041 · Cited by 74 · see citing works

Engineering antibody and protein therapeutics to cross the blood–brain barrier

Zhao, P., Zhang, N., & An, Z. (2022) · Antibody Therapeutics · doi:10.1093/abt/tbac028 · Cited by 71 · see citing works

Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer’s Disease: A Systematic Review and Meta-Analysis

Penninkilampi, R., Brothers, H. M., & Eslick, G. D. (2016) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-016-9722-5 · Cited by 69 · see citing works

SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-β antibody in a mouse model of Alzheimer’s disease

Gustavsson, T., Syvänen, S., O’Callaghan, P., & Sehlin, D. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00214-1 · Cited by 69 · see citing works

Disaggregation of Amyloid Plaque in Brain of Alzheimer’s Disease Transgenic Mice with Daily Subcutaneous Administration of a Tetravalent Bispecific Antibody That Targets the Transferrin Receptor and the Abeta Amyloid Peptide

Sumbria, R. K., Hui, E. K., Lu, J. Z., Boado, R. J., & Pardridge, W. M. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400348n · Cited by 65 · see citing works

Mouse Models for Drug Discovery. Can New Tools and Technology Improve Translational Power?

Zuberi, A. R., & Lutz, C. M. (2016) · ILAR Journal · doi:10.1093/ilar/ilw021 · Cited by 65 · see citing works

Neutralization of Soluble, Synaptotoxic Amyloid β Species by Antibodies Is Epitope Specific

Zago, W., Buttini, M., Comery, T. A., Nishioka, C., Gardai, S. J., Seubert, P., Games, D., Bard, F., Schenk, D., & Kinney, G. G. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1676-11.2012 · Cited by 62 · see citing works

Imaging endpoints for clinical trials in Alzheimer’s disease

Cash, D. M., Rohrer, J. D., Ryan, N. S., Sebastien Ourselin, A., & Fox, N. C. (2014) · Alzheimer s Research & Therapy · doi:10.1186/s13195-014-0087-9 · Cited by 62 · see citing works

Vascular alterations in PDAPP mice after anti‐Aβ immunotherapy: Implications for amyloid‐related imaging abnormalities

Zago, W., Schroeter, S., Guido, T., Khan, K., Seubert, P., Yednock, T., Schenk, D., Gregg, K. M., Games, D., Bard, F., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.010 · Cited by 75 · see citing works

An MRI Rating Scale for Amyloid-Related Imaging Abnormalities with Edema or Effusion

Barkhof, F., Daams, M., Scheltens, P., Brashear, H. R., Arrighi, H. M., Bechten, A., Morris, K., McGovern, M., & Wattjes, M. P. (2013) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3475 · Cited by 60 · see citing works

Bapineuzumab: Anti-β-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer‘s Disease

Panza, F., Frisardi, V., Imbimbo, B. P., D’Onofrio, G., Pietrarossa, G., Seripa, D., Pilotto, A., & Solfrizzi, V. (2010) · Immunotherapy · doi:10.2217/imt.10.80 · Cited by 58 · see citing works

First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease

Delnomdedieu, M., Duvvuri, S., Li, D. J., Atassi, N., Lu, M., Brashear, H. R., Liu, E., Ness, S. L., & Kupiec, J. W. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0177-y · Cited by 59 · see citing works

Antibody-based therapy in Alzheimer's disease

Pul, R., Dodel, R. C., & Stangel, M. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.552884 · Cited by 58 · see citing works

Activation of matrix metalloproteinases following anti-Aβ immunotherapy; implications for microhemorrhage occurrence

Wilcock, D., Morgan, D., Gordon, M., Taylor, T. L., Ridnour, L., Wink, D., & Colton, C. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-115 · Cited by 52 · see citing works

Re-engineering therapeutic antibodies for Alzheimer’s disease as blood-brain barrier penetrating bi-specific antibodies

Pardridge, W. M. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1230195 · Cited by 55 · see citing works

Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before

Mancuso, C., Siciliano, R., Barone, E., Butterfield, D. A., & Preziosi, P. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.601740 · Cited by 52 · see citing works

Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer’s-like mice

Crehan, H., Liu, B., Kleinschmidt, M., Rahfeld, J., Le, K. X., Caldarone, B. J., Frost, J. L., Hettmann, T., Hutter‐Paier, B., O’Nuallain, B., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0579-8 · Cited by 48 · see citing works

Analysis of recent failures of disease modifying therapies in Alzheimer’s disease suggesting a new methodology for future studies

Amanatkar, H. R., Papagiannopoulos, B., & Grossberg, G. T. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1194203 · Cited by 47 · see citing works

Autoantibodies with enzymatic properties in human autoimmune diseases

Wootla, B., Lacroix‐Desmazes, S., Warrington, A. E., Bieber, A. J., Kaveri, S. V., & Rodriguez, M. (2011) · Journal of Autoimmunity · doi:10.1016/j.jaut.2011.05.007 · Cited by 44 · see citing works

Blood-brain barrier integrity in a mouse model of Alzheimer's disease with or without acute 3D6 immunotherapy

Gustafsson, S. S., Gustavsson, T., Roshanbin, S., Hultqvist, G., Hammarlund‐Udenaes, M., Sehlin, D., & Syvänen, S. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.09.001 · Cited by 42 · see citing works

Alzheimer’s Disease: Drug Discovery

Huang, X. (2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020 · Cited by 45 · see citing works

Monoclonal Antibody Therapy in Alzheimer’s Disease

Neațu, M., Covaliu, A., Ioniță, I., Jugurt, A., Davidescu, E. I., & Popescu, B. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010060 · Cited by 43 · see citing works

Anti-Aβ Antibodies and Cerebral Amyloid Angiopathy Complications

Chantran, Y., Capron, J., Alamowitch, S., & Aucouturier, P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01534 · Cited by 42 · see citing works

Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer’s Disease

Behl, T., Kaur, I., Frățilă, O., Brata, R. D., & BUNGAU, S. G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207443 · Cited by 46 · see citing works

Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies

Brashear, H. R., Ketter, N., Bogert, J., Di, J., Salloway, S., & Sperling, R. A. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180675 · Cited by 39 · see citing works

Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer’s Disease: A Systematic Review and Network Meta-Analysis

Qiao, Y., Gu, J., Yu, M., Chi, Y., & Ma, Y. (2024) · CNS Drugs · doi:10.1007/s40263-024-01067-2 · Cited by 38 · see citing works

Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads

Panza, F., Frisardi, V., Imbimbo, B. P., Seripa, D., Solfrizzi, V., & Pilotto, A. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.579099 · Cited by 38 · see citing works

Early Stage Glycosylation Biomarkers in Alzheimer’s Disease

Regan, P., McClean, P. L., Smyth, T. J., & Doherty, M. (2019) · Medicines · doi:10.3390/medicines6030092 · Cited by 36 · see citing works

Immunotherapy for Alzheimer's Disease: Current Scenario and Future Perspectives

Usman, M. B., Bhardwaj, S., Roychoudhury, S., Kumar, D., Alexiou, A. T., Kumar, P., Ambasta, R. K., Prasher, P., Shukla, S. D., Upadhye, V. J., et al. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.52 · Cited by 37 · see citing works

Inflammatory cerebral amyloid angiopathy and amyloid‐modifying therapies: Variations on the Same ARIA?

Werring, D. J., & Sperling, R. A. (2013) · Annals of Neurology · doi:10.1002/ana.23891 · Cited by 34 · see citing works

First Administration of the Fc-Attenuated Anti-β Amyloid Antibody GSK933776 to Patients with Mild Alzheimer’s Disease: A Randomized, Placebo-Controlled Study

Andreasen, N., Simeoni, M., Östlund, H., Lisjö, P., Fladby, T., Loercher, A. E., Byrne, G. J., Murray, F., Scott‐Stevens, P., Wallin, A., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0098153 · Cited by 34 · see citing works

Bapineuzumab Alters Aβ Composition: Implications for the Amyloid Cascade Hypothesis and Anti-Amyloid Immunotherapy

Roher, A. E., Cribbs, D. H., Kim, R. C., Maarouf, C. L., Whiteside, C. M., Kokjohn, T. A., Daugs, I. D., Head, E., Liebsack, C., Serrano, G. E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059735 · Cited by 34 · see citing works

Controversial Past, Splendid Present, Unpredictable Future: A Brief Review of Alzheimer Disease History

Bermejo‐Pareja, F., & del Ser, T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020536 · Cited by 35 · see citing works

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer’s disease

Brody, M., Liu, E., Di, J., Lu, M., Margolin, R. A., Werth, J. L., Booth, K., Shadman, A., Brashear, H. R., & Novak, G. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160369 · Cited by 32 · see citing works

The Impact of Anti-Amyloid Immunotherapies on Stroke Care

Bilodeau, P., Dickson, J. R., & Kozberg, M. G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051245 · Cited by 31 · see citing works

Alzheimer’s Disease: Lessons Learned from Amyloidocentric Clinical Trials

Soejitno, A., Tjan, A., & Purwata, T. E. (2015) · CNS Drugs · doi:10.1007/s40263-015-0257-8 · Cited by 31 · see citing works

Emerging Promise of Immunotherapy for Alzheimer’s Disease: A New Hope for the Development of Alzheimer’s Vaccine

Kabir, M. T., Uddin, M. S., Mathew, B., Das, P. K., Perveen, A., & Ashraf, G. M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200422105156 · Cited by 31 · see citing works

Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody

Haraya, K., Tachibana, T., Nanami, M., & Ishigai, M. (2014) · Xenobiotica · doi:10.3109/00498254.2014.941963 · Cited by 30 · see citing works

Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs

Froestl, W., Pfeifer, A., & Muhs, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121729 · Cited by 27 · see citing works

Theoretical Analysis of Interplay of Therapeutic Protein Drug and Circulating Soluble Target: Temporal Profiles of ‘Free’ and ‘Total’ Drug and Target

Tang, C., & Prueksaritanont, T. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0471-0 · Cited by 27 · see citing works

Prophylaxis and Treatment of Alzheimer's Disease by Delivery of an Adeno-Associated Virus Encoding a Monoclonal Antibody Targeting the Amyloid Beta Protein

Shimada, M., Abe, S., Takahashi, T., Shiozaki, K., Okuda, M., Mizukami, H., Klinman, D. M., Ozawa, K., & Okuda, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057606 · Cited by 27 · see citing works

Modulation of Amyloid Aggregates into Nontoxic Coaggregates by Hydroxyquinoline Appended Polyfluorene

Chowdhury, S. R., Agarwal, M., Meher, N., Balakrishnan, M., & Iyer, P. K. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b03668 · Cited by 26 · see citing works

Disease Modifying Drugs Targeting β-Amyloid

Ozudogru, S. N., & Lippa, C. F. (2012) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317512452034 · Cited by 25 · see citing works

Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders

Vissers, M. F. J. M., Heuberger, J. A. A. C., & Groeneveld, G. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041615 · Cited by 24 · see citing works

Immunotherapy for Parkinson’s Disease and Alzheimer’s Disease: A Promising Disease-Modifying Therapy

Mahboob, A., Ali, H., Naimi, A. J. A., Yousef, M., Rob, M., Al-Muhannadi, N. A., Senevirathne, D. K. L., & Châari, A. (2024) · Cells · doi:10.3390/cells13181527 · Cited by 25 · see citing works

Amyloid-Related Imaging Abnormalities in an Aged Squirrel Monkey with Cerebral Amyloid Angiopathy

Heuer, E., Jacobs, J. T., Du, R. Y., Wang, S., Keifer, O. P., Cintron, A. F., Dooyema, J. M., Meng, Y., Zhang, X., & Walker, L. C. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160981 · Cited by 23 · see citing works

Physiologically Based Modeling to Predict Monoclonal Antibody Pharmacokinetics in Humans from in vitro Physiochemical Properties

Hu, S., Datta‐Mannan, A., & D’Argenio, D. Z. (2022) · mAbs · doi:10.1080/19420862.2022.2056944 · Cited by 23 · see citing works

Therapeutic anti‐amyloid β antibodies cause neuronal disturbances

Adhikari, U. K., Khan, R. H., Mikhael, M., Balez, R., David, M. A., Mahns, D. A., Hardy, J., & Tayebi, M. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12833 · Cited by 24 · see citing works

P4‐210: Safety, tolerability and pharmacokinetics of single‐ascending doses of bapineuzumab in Japanese patients with mild‐to‐moderate Alzheimer's disease

Arai, H., Umemura, K., Ichimiya, Y., Iseki, E., Eto, K., Shibata, N., Baba, H., Tsuchiwata, S., Miyasato, M., & Ishikawa, N. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.05.2233

Safety and pharmacokinetics of bapineuzumab in a single ascending‐dose study in J apanese patients with mild to moderate A lzheimer's disease

Arai, H., Umemura, K., Ichimiya, Y., Iseki, E., Eto, K., Miyakawa, K., Kirino, E., Shibata, N., Baba, H., & Tsuchiwata, S. (2015) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.12516 · Cited by 19 · see citing works

P3‐246: Pharmacokinetics and pharmacodynamics of bapineuzumab following multiple intravenous infusions in patients with mild‐to‐moderate Alzheimer's disease

Raskind, M. A., Liang, E., Sperling, R. A., Boxer, A. L., Ross, J., Brody, M., Garzone, P. D., Raje, S. V., Black, R. S., & Grundman, M. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.1019 · Cited by 2 · see citing works

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Bapineuzumab: A Single‐Ascending‐Dose Study in Patients With Mild to Moderate Alzheimer Disease

Lu, M., & Brashear, H. R. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.584 · Cited by 11 · see citing works

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753 · see citing works